Resistant hypertension and renal denervation: 3 years on
2013; Elsevier BV; Volume: 383; Issue: 9917 Linguagem: Inglês
10.1016/s0140-6736(13)61999-6
ISSN1474-547X
Autores Tópico(s)Sodium Intake and Health
ResumoIn 2009, Henry Krum and colleagues 1 Krum H Schlaich M Whitbourn R et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009; 373: 1275-1281 Summary Full Text Full Text PDF PubMed Scopus (1745) Google Scholar published the initial report of the landmark Symplicity HTN-1 trial, which assessed the blood-pressure-lowering action of renal denervation (RDN) in patients with resistant hypertension (figure). It immediately created a ripple in the worldwide hypertension community and refocused attention on the kidney and its innervation as therapeutic targets for the treatment of chronically raised blood pressure. 1 Krum H Schlaich M Whitbourn R et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009; 373: 1275-1281 Summary Full Text Full Text PDF PubMed Scopus (1745) Google Scholar , 2 DiBona GF Esler M Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol. 2010; 298: R245-R253 Crossref PubMed Scopus (323) Google Scholar At the time of reporting, patients had been followed-up for 12 months. Now, in The Lancet, Krum and colleagues report the 3-year outcomes, 3 Krum H Schlaich MP Böhm M et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2013; (published online Nov 7.)http://dx.doi.org/10.1016/S0140-6736(13)62192-3 PubMed Google Scholar which extend the observations in 88 of the original cohort of 153 patients. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 studyChanges in blood pressure after RDN persist long term in patients with treatment-resistant hypertension, with good safety. Full-Text PDF
Referência(s)